RETREAT Score Accurately Predicts the Long-Term Risk of HCC Recurrence After Liver Transplantation: A Single-Center Real-Life Validation
Authors:
- Flavia NeriFNFlavia Neri
- Mauro ViganòMauro Viganò
- Stefania CamagniSCStefania Camagni
- Marco Fabrizio ZambelliMZMarco Fabrizio Zambelli
- Alessandro LoglioAlessandro Loglio
- Massimo De GiorgioMGMassimo De Giorgio
- Riccardo MugliaRMRiccardo Muglia
- Lisa LiciniLLLisa Licini
- Andrea FrancavillaAFAndrea Francavilla
- Paolo MarraPMPaolo Marra
- Sandro SironiSSSandro Sironi
- Paola Anna ErbaPEPaola Anna Erba
Open Access
Abstract
Background: Liver transplantation (LT) for Hepatocellular carcinoma (HCC) is still burdened by a significant risk of tumor recurrence. The aim of this study was to apply the Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for prediction of HCC recurrence and survival. Methods: This retrospective study included all adult patients who consecutively underwent LT for HCC from January 2000 to July 2022 at a single institution. Results: During a median follow-up of 64 months, 56 (19%) out of 298 patients [54%, 36% and 10% with a RETREAT score equal to 0/1 (low), 2/3 (medium) and 4–6 (high), respectively] experienced HCC recurrence after a median of 31 months. The HCC recurrence rates at 1, 5 and 10 years were respectively 4%, 16% and 23%. The 5-year RFS for low-, medium- and high-risk groups were 93%, 78% and 58% (p < 0.001), respectively. In the competitive risk analysis, the medium- and high-risk RETREAT groups had respectively a 2.3 HR (p = 0.017) and 6.4 HR (p < 0.001) of HCC recurrence compared with the low-risk group. Overall, 119 patients died [32 (27%) due to HCC recurrence], and the 5-year survival was 74% (95%, 86% and 61% for low-, medium- and high-risk groups, respectively). In the multivariate analysis, the RETREAT score was associated with the overall survival only for the highest risk class, which yielded a 2.5 HR of death compared with the lowest risk categories (p < 0.001). Conclusions: This study validates the RETREAT score and confirms its ability to predict the risk of HCC recurrence.Keywords
This publication has 27 references indexed in Scilit:
- Recent Advances in Liver Transplantation for Hepatocellular CarcinomaCurrent Treatment Options in Oncology, 2024
- Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular CarcinomaJAMA Surgery, 2022
- Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohortHPB, 2022
- Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humansJournal of Hepatology, 2018
- Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver TransplantJAMA Oncology, 2017
- Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCCJournal of Hepatology, 2017
- A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus–infected mongoliansHepatology, 2016
- Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policyLiver Transplantation, 2013
- Obliterative portal venopathy: Portal hypertension is not always present at diagnosisJournal of Hepatology, 2011
- Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysisThe Lancet Oncology, 2009